EMA — authorised 8 March 2002
- Application: EMEA/H/C/000391
- Marketing authorisation holder: AbbVie Deutschland GmbH & Co. KG
- Local brand name: Lumigan
- Indication: Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).
- Status: approved